Weekly Dose-Dense Chemotherapy as First-Line for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The final report of the ICON-8 trial closes the debate as to whether weekly chemo is more effective than the standard chemo.
A clinical trial in 2008 involving Japanese women (JGOC 3016) reported a survival benefit for women with ovarian cancer whose chemo frequency was increased from the normal one dose every three weeks to a weekly dose regimen.
Some doubt about the benefit for the general population remained and a large clinical trial involving 1566 patients (ICON-8) began in 2011, with random allocation to either standard or weekly chemo. The final results are now available. There is no survival benefit for non-Japanese women. Adverse side effects were commoner with weekly chemo.
No comments:
Post a Comment